Müller M J, Gründer G, Wetzel H, Müller-Siecheneder F, Marx-Dannigkeit P, Benkert O
Department of Psychiatry, University of Mainz, Germany.
Psychiatry Res. 1999 Dec 27;89(3):275-80. doi: 10.1016/s0165-1781(99)00100-6.
Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.
在12名符合精神分裂症DSM-III-R标准的患者（6名男性，6名女性）中，研究了选择性σ配体EMD 57445（帕纳美辛）的抗精神病疗效和副作用。一项为期4周的开放性临床研究表明，EMD 57445及其代谢产物对精神分裂症的阳性和阴性症状仅有适度影响。锥体外系及其他副作用为中度，不过发现轻度运动障碍有显著增加。5名患者完成了试验，其中4名是女性。退出试验主要是由于治疗失败。女性患者的抗精神病效果显著优于男性患者。
